METIS TECHBIO-P Climbs Nearly 6% in Morning Trade as Institution Expects AiLNP Platform Value to Keep Materializing

Deep News10-28

METIS TECHBIO-P (07666) rose nearly 7% during intraday trading. As of press time, the stock was up 5.59%, quoted at HK$11.52, with turnover of HK$43.35224 million.

Recently, METIS TECHBIO-P announced the signing of a strategic collaboration with Eli Lilly to jointly advance next-generation tissue-specific LNP delivery technology. METIS TECHBIO-P will leverage its NanoForge-driven AiLNP platform to develop next-generation LNP delivery technology, while Eli Lilly will contribute drug discovery, development, and commercialization resources to advance the collaboration. METIS TECHBIO-P will receive an upfront payment of more than tens of millions of US dollars, milestone payments of up to US$1.1 billion, and tiered royalties.

Haitong International believes that this collaboration with global leading pharmaceutical company Eli Lilly further validates the differentiated value of the company's AiLNP delivery technology and NanoForge platform, earning endorsement from a major international pharmaceutical firm. Demand for extrahepatic delivery in the pharmaceutical industry is expected to continue growing, and the company's AiLNP technology platform has already established a certain first-mover advantage, with its platform value expected to keep materializing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment